Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 12/20 | 0.51 |
| ▸ | F11 | P03951 | 2/20 | 0.49 |
| ▸ | TPSB2 | P20231 | 2/20 | 0.49 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.49 |
| ▸ | F7 | P08709 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25879182 | 0.92 | CFD (0.54) | CFDF11TPSB2PLGPLAU | |
| SCHEMBL25883812 | 0.91 | CFD (0.45) | CFDF11TPSB2PLGPLAU | |
| SCHEMBL25879295 | 0.89 | CFD (0.56) | CFDF11TPSB2PLGPLAU | |
| SCHEMBL25879270 | 0.89 | CFD (0.52) | CFDF11TPSB2PLGPLAU | |
| SCHEMBL21438468 | 0.89 | CFD (0.64) | CFDF11TPSB2PLGPLAU | |
| SCHEMBL21437778 | 0.89 | CFD (0.49) | CFDF11TPSB2PLGPLAU | |
| SCHEMBL25879282 | 0.87 | CFD (0.47) | CFDF11TPSB2PLGPLAU | |
| SCHEMBL25879271 | 0.86 | CFD (0.45) | CFDF11TPSB2PLGPLAU | |
| SCHEMBL21438502 | 0.86 | CFD (0.69) | CFDF11TPSB2PLGPLAU | |
| SCHEMBL25879284 | 0.84 | CFD (0.58) | CFDF11TPSB2PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | CFD 17/4885F11 216/4885TPSB2 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.